← Back to Clinical Trials
Recruiting NCT06983366

NCT06983366 Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06983366
Status Recruiting
Phase
Sponsor Assiut University
Condition COPD
Study Type OBSERVATIONAL
Enrollment 700 participants
Start Date 2025-05-30
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Lung Ultrasound

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 700 participants in total. It began in 2025-05-30 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.

Eligibility Criteria

Inclusion Criteria: * Age 18 years and older. * Diagnosed with one of the specified pulmonary diseases, or a healthy control * Able to provide written informed consent Exclusion Criteria: * Inability to tolerate or undergo a lung ultrasound * Extensive chest wall pathology precluding assessment * Unscorable \>2 zones per protocol * Withdrawal of consent * Mechanically-ventilated patients

Contact & Investigator

Central Contact

Ahmad M. Shaddad, MD

✉ shaddad_ahmad@yahoo.com

📞 +201111171930

Principal Investigator

Ahmad M. Shaddad, MD

PRINCIPAL INVESTIGATOR

Assiut University

Frequently Asked Questions

Who can join the NCT06983366 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06983366 currently recruiting?

Yes, NCT06983366 is actively recruiting participants. Contact the research team at shaddad_ahmad@yahoo.com for enrollment information.

Where is the NCT06983366 trial being conducted?

This trial is being conducted at Asyut, Egypt.

Who is sponsoring the NCT06983366 clinical trial?

NCT06983366 is sponsored by Assiut University. The principal investigator is Ahmad M. Shaddad, MD at Assiut University. The trial plans to enroll 700 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology